Otezla Shortage Update: What Patients Need to Know in 2026

If you've searched online for an 'Otezla shortage' or found yourself unable to fill your prescription, you're understandably confused. Otezla (apremilast) is not listed on the FDA Drug Shortages Database as of 2026 — meaning there is no formal supply shortage of the medication. Amgen continues to manufacture and distribute the drug consistently. But here's the important distinction: not being in shortage doesn't mean Otezla is easy to access. There are significant structural barriers that make getting Otezla genuinely difficult for many patients. This update explains what's really going on and what you can do about it.

Is Otezla in Shortage in 2026?

No. As of 2026, Otezla is not listed on the FDA's Drug Shortages Database. Amgen, which acquired Otezla from Celgene in 2019, manufactures and distributes the drug through a stable supply chain. There are no reported manufacturing disruptions, raw material shortages, or distribution problems affecting Otezla's availability at the supply level.

However, patients consistently report difficulty accessing the medication — delays of weeks, outright denials, or cost-related inability to fill the prescription. These are real barriers, but they are access barriers, not supply barriers. Understanding this distinction is crucial to solving the problem.

Why Patients Still Struggle to Get Otezla

The access challenges with Otezla stem from several distinct factors:

Specialty pharmacy requirement: Otezla is not available at regular retail pharmacies. It can only be dispensed through specialty pharmacies in Amgen's distribution network, which not all patients are aware of when first prescribed.

Insurance prior authorization: Most insurance plans require prior authorization, which takes 1 to 4 weeks to process. Until approved, most patients cannot fill their prescription under their insurance benefit.

Step therapy requirements: Many plans require patients to try and fail on cheaper medications like methotrexate before covering Otezla, adding months to the access timeline.

High out-of-pocket costs: At approximately $5,000 to $6,800 per month without insurance, Otezla is unaffordable without financial assistance. No US generic is available until approximately 2028-2029.

Insurance network restrictions: Some insurance plans restrict Otezla to specific in-network specialty pharmacies, which may not be conveniently located or may have longer processing times.

What Has Changed for Otezla Patients in 2026

Several important changes affect Otezla patients in 2026. The Inflation Reduction Act's Medicare Part D out-of-pocket cap took effect in 2025, limiting annual drug costs to $2,000 for Medicare beneficiaries — a significant benefit for patients on fixed incomes who take Otezla. Patients on Medicare should contact their plan or call 1-800-633-4227 to verify their specific coverage.

Additionally, the extended-release formulation Otezla XR (75 mg once daily) continues to provide an alternative dosing option for patients who find twice-daily dosing inconvenient. Some insurance plans may have different formulary placement for Otezla vs. Otezla XR, so it's worth asking your pharmacy benefits team if one formulation has a lower copay for your plan.

On the patent front, Amgen's patents on Otezla were upheld by an April 2023 court ruling, pushing the expected US generic launch to approximately 2028-2029. Until then, patients must navigate the brand-name drug pricing and savings programs.

What Patients Should Do Right Now

If you're having trouble accessing Otezla in 2026, here are the most impactful steps:

Enroll in Amgen SupportPlus: Call 1-833-442-6436 or visit otezla.com/enroll. This is your gateway to the copay card, bridge program, and insurance support team.

Use the Bridge Program: If you have commercial insurance and your PA is delayed, the Bridge to Commercial Coverage program provides free Otezla for up to 12 fills. Don't wait for approval to start treatment.

Request an expedited PA review: If your condition is severe or worsening, your doctor can request an expedited review (also called urgent PA), which insurers are required to process within 72 hours in most states.

Appeal a denial: If your PA was denied due to step therapy requirements, work with your doctor to document why the required first-line drugs are inappropriate or were already tried. Appeal rates for Otezla are often successful with thorough documentation.

Ask about Otezla XR: Some patients find better formulary coverage with one formulation over the other. Ask your insurer if Otezla XR (75 mg once daily) has different cost-sharing under your plan.

The Bottom Line for Patients in 2026

Otezla is not in shortage in 2026 — it's in a specialty access situation driven by insurance requirements and pricing. With the right enrollment in Amgen SupportPlus and proactive PA management, most patients can get their medication. medfinder can help you locate pharmacies that can fill your prescription, and our guide on How to Save Money on Otezla in 2026 outlines every financial assistance option available.